Todd C. Brady's most recent trade in Aldeyra Therapeutics Inc was a trade of 250,000 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on June 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.67 per share. | 03 Jun 2026 | 250,000 | 1,721,298 (6%) | 0% | 1.7 | 418,450 | Common Stock |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2026 | 1,880,510 | 1,880,510 | - | - | Stock Option (right to buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2026 | 632,318 | 632,318 | - | - | Bonus Units | |
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 1,187 | 8,238 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 809,710 | 809,710 | - | - | Stock Option (right to buy) | |
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 5,833 | 5,833 | - | - | Stock Option (Right to Buy) | |
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 14,625 | 14,625 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2024 | 1,081,201 | 1,081,201 | - | - | Stock Option (right to buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.27 per share. | 09 Mar 2024 | 97,914 | 1,556,622 (5%) | 0% | 3.3 | 320,521 | Common Stock |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.05 per share. | 09 Mar 2024 | 85,324 | 1,471,298 (5%) | 0% | 3.0 | 260,238 | Common Stock |
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 14,625 | 14,625 | - | - | Stock Option (Right to Buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 238,750 | 1,455,285 (5%) | 0% | 0 | Common Stock | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 604,308 | 604,308 | - | - | Bonus Units | |
| Aldeyra Therapeutics Inc | Todd C. Brady | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.36 per share. | 23 Jun 2022 | 17,700 | 1,216,535 (4%) | 0% | 3.4 | 59,546 | Common Stock |
| Evoke Pharma Inc | Todd C. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2022 | 57,750 | 57,750 | - | - | Stock Option (Right to Buy) |